We describe here the case of an 8-year-old girl with Fanconi anemia (FA) whose hematopoiesis was successfully restored by unrelated umbilical cord blood (UCB) transplantation. The patient became resistant to androgen therapy, and developed intracranial hemorrhage and dyserythropoiesis. Her hematopoietic recovery after the transplantation was excellent and a complete chimerism has been durably maintained. UCB should be considered as a stem cell source for transplantation when a patient with FA does not have an HLA-identical unaffected sibling donor. Bone Marrow Transplantation (2001) 27, 767-769.
Fanconi anemia (FA) is an inherited bone marrow failure syndrome characterized by congenital malformations and chromosomal instability. Most FA patients show progressive aplasia and eventually develop myelodysplastic syndrome, acute myelogeneous leukemia, or other cancers. 1 It has been shown that allogeneic BMT from an HLAmatched unaffected sibling donor is effective in restoring a normal hematopoiesis in patients with FA. 2 However, more than 70% of the patients who would benefit from the transplantation do not have a suitable matched sibling donor, and alternative sources of hematopoietic cell have been explored in an attempt to meet their needs. Recently, increasing numbers of successful unrelated umbilical cord blood (UCB) transplantations have been reported, particularly in pediatric patients with hematological neoplasms. [3] [4] [5] For bone marrow failure syndromes, however, only a limited number of patients have received UCB transplantation and its feasibility is still ambiguous. 4, 5 We report a successful UCB transplantation in an 8-yearold girl with FA who needed hematopoietic restoration 
Case report
A 4-year-old girl began to receive medical attention in October 1994 for petechiae and pallor combined with some malformations (Table 1) . She was a twin born to nonconsanguineous parents at 7 months' gestation. The other twin, who was a boy, died from congenital abnormalities at 2 months. There is no family history of hematological disorder. The diagnosis of FA was established in July 1995 based on a diagnostic laboratory test using metaphase preparations of cultured peripheral blood lymphocytes. 6 When a clastogenic agent, diepoxybutane (0.1 g/ml), was added to the culture of her cells, the mean number of chromosome breaks was 23.2/cell while the control ranged from 0.00 to 0.10/cell. Her CBC revealed WBC 2.8 × 10 9 /l, Hb 9.4 g/dl, and platelets 24 × 10 9 /l. She was not given any medication at that time. She was referred to our hospital in September 1995 for further medical care. Androgen therapy was initiated because the progression of anemia (Hb 3.9 g/dl) and thrombocytopenia (platelets 11 × 10 9 /l) were noted. Single-strand conformational polymorphism analysis was performed to screen the genomic DNA of the patient in exons and flanking intronic regions 1, 4 and 14 for the FA group C gene. [7] [8] [9] No mutation was detected in these /l and the coagulation test, however, was normal. She required multiple platelet transfusions. Magnetic resonance angiography of the brain showed occlusive lesions in the left middle cerebral artery and both anterior cerebral arteries accompanied by puff-like vessels (ie moyamoya-like anomaly). 10 The main cause of the hemorrhage, however, was thought to be the thrombocytopenia. Bone marrow aspirate revealed the progression of dyserythropoietic features with less than 1% myeloblasts. Although cytogenetic study of the marrow cells showed a normal karyotype, an urgent hematopoietic stem cell transplantation utilizing UCB was warranted.
In May 1999 (aged 8), she received a preparative regimen consisting of thoracoabdominal irradiation (TAI, 5 Gy in fractions of 2.5 Gy two times a day delivered at a dose rate of 10 cGy/min on day −7), rabbit anti-human thymocyte immunoglobulin (Thymoglobuline; Pasteur Mérieux, Lyon, France, 2.5 mg/kg, days −6 to −3) and CY (10 mg/kg, days −5 to −2). For the TAI, the right lobe of the liver and urinary bladder were shielded and the dose for the kidneys was reduced by half. She received a UCB unit from a male donor. The number of infused cells was 2.78 × 10 7 total nucleated cells/kg that comprised 1.87 × 10 5 CD34 + cells/kg and 7.76 × 10 4 colony-forming cells/kg recipient weight. The patient and donor were serologically one antigen mismatched and two loci mismatched as determined by DNA typing. A major ABO incompatibility was found between donor and recipient ( Table 2) . Cytomegalovirus serology of the patient was positive. Methylprednisolone (mPSL) and CsA were given for the GVHD prophylaxis. She showed a prompt hematological recovery in the myeloid lineage with the achievement of an absolute neutrophil count of over 500/l on day +13. The final transfusion support of platelets and RBC was on days +54 and +43, respectively. The post-transplant period was complicated by respiratory distress on day +9, successfully managed with dexamethasone, and mild hemorrhagic cystitis from days +26 to +35. Chimerism evaluation assessed by FISH using a mixture of X and Y chromosomespecific probes revealed that more than 97% of blood cells showed XY signal on day +13, day +140 and 12 months after the transplantation. The overall clinical grading of acute GVHD was grade I and there have been no clinical signs of chronic GVHD. At the time of writing, 19 months after the transplantation, the patient is alive with a perfect performance status and normal blood count.
Discussion
Allogeneic hematopoietic cell transplantation is the only treatment restoring normal hematopoiesis in patients with FA. 1 However, early experiences with BMT for FA were negative primarily because of excessive regimen-related toxicity and severe acute GVHD.
11, 12 Gluckman et al 2, 11 proposed a reduced dose of CY (20 mg/kg) and TAI (5 Gy) as a preparative regimen for BMT because FA patients may have increased sensitivity to CY and radiation in doses commonly used for pretransplant conditioning. Yabe et al 13 suggested that individual dose adjustment of CY for preconditioning based on the in vitro effect of CY metabolites on chromosomes might be beneficial to FA patients. Along with these efforts to improve the conditioning regimens for FA, the efficacy of BMT using an HLA-identical unaffected sibling donor has been established. 2, [12] [13] [14] [15] Unrelated donor BMT for FA, however, has been hampered mainly because of the high incidence of graft failure and severe acute GVHD. 2, 16, 17 Recently, UCB has been utilized as an alternative hematopoietic stem cell source that can restore and maintain normal hematopoiesis with a low incidence of severe GVHD when compared with unrelated donor BMT. 4, 5, [18] [19] [20] Although promising results from UCB transplantation have been reported, particularly in pediatric patients with hematological malignancies, the efficacy of UCB transplantation for bone marrow failure syndromes including FA is still questionable because the likelihood of successful engraftment is significantly reduced. 4, 5 In our patient, however, the serious intracranial hemorrhage, the progression of dysplastic hematopoiesis, and the absence of a suitable marrow donor allowed us to perform the UCB transplantation. Several favorable factors in the transplantation for FA have been postulated such as less frequent transfusions before transplantation, 21 preconditioning including ATG and dose reduction in chemoradiotherapy, 16 prophylaxis of GVHD with CsA and mPSL, 16 and pretransplant serum alanine/aspartate transaminase values less than twice the upper normal value. 17 Our case does have these features and, in fact, the hematopoietic recovery of the patient was excellent and transplant-related short-term toxicity was mild. Nonetheless, the major concern about CB transplantation is whether a given CB unit has enough potential to achieve durable lymphohematopoietic engraftment in a patient. There has been no clue except for infused nucleated cell dose that may guarantee the engraftment. 5, 18 Furthermore, our xenoplantation model in NOD/SCID mice revealed that there was substantial heterogeneity among CB units in terms of their potential for reconstitution. 22 Even in the in vitro clonal cell culture system detecting much more mature progenitors, the frequency of the colony-forming cells varied among CB units (unpublished data). Once a technique to tell the potential of a given CB unit as a stem cell source is established, UCB transplantation will be much more widely applied for various kinds of defects in the lymphohematopoietic system.
